IMU

0.00%

3.6¢

IMUGENE LIMITED

Market Cap $267.7M Add to my watchlist

Healthcare Biotechnology

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. WEBINAR: What investors should know about what it takes for ASX-listed companies to get medical developments...

Latest Threads

Tag

Subject

IMU

Why IMU is a multi multi bagger

472 473 474

03:52

28K

14M

03:52

Last post DDD24

28K

14M

IMU

Ann: Proposed issue of securities - IMU

27/12/24

14K

27/12/24

Last post valueadd

14K

IMU Biotech

IMUGENE CHART. TA only

594 595 596

26/12/24

35K

17M

26/12/24

Last post

slick

35K

17M

IMU

Extraordinary General Meeting

24/12/24

22K

24/12/24

Last post 4678346

22K

IMU

Ann: Issuance of Convertible Notes & Warrants for up to $46m

24/12/24

39K

24/12/24

Last post AlCp

39K

IMU

EGM for Cap raising announced via email

24/12/24

9.2K

24/12/24

Last post lbraz4me

9.2K

IMU

Media Thread

283 284 285

23/12/24

17K

8.1M

23/12/24

Last post changa2

17K

8.1M

IMU Biotech

Extraordinary meeting

23/12/24

3.3K

23/12/24

Last post Wantawin3

3.3K

See All Discussions

Timeline

Proposed issue of securities - IMU
24 Dec 08:38	Share

Notice of Extraordinary General Meeting/Proxy Form
23 Dec 18:25	Share

Issuance of Convertible Notes & Warrants for up to $46m
23 Dec 17:29	Share

Azer-cel Accepted for Presentation at ASTCT Tandem Meetings
20 Dec 13:20	Share

Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund
19 Dec 08:54	Share

Updated Appendix 3Z
20 Nov 18:25	Share

Final Director's Interest Notice
20 Nov 17:13	Share

Director Resignation
15 Nov 08:23	Share

Imugene 2024 AGM Results
14 Nov 13:59	Share

Imugene AGM Presentation
14 Nov 08:24	Share

onCARlytics Trial Doses First Patient in IT Combination Arm
11 Nov 09:03	Share

Imugene Opens First Australian Site for azer-cel Trial
08 Nov 10:08	Share

Complete Response in MAST Study Maintained Over Two Years
05 Nov 09:04	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Oct 09:10	Share

Notification regarding unquoted securities - IMU
14 Oct 16:40	Share

Notification of cessation of securities - IMU
14 Oct 16:37	Share

Application for quotation of securities - IMU
14 Oct 16:36	Share

Notice of Annual General Meeting/Proxy Form
14 Oct 16:28	Share

Change of Director's Interest Notice - PH
30 Sep 17:01	Share

Imugene Receives Orphan Drug Designation for VAXINIA
18 Sep 13:06	Share

Appendix 2A
11 Sep 16:59	Share

Imugene Corporate Presentation
09 Sep 10:12	Share

Cleansing Notice
04 Sep 16:32	Share

Application for quotation of securities - IMU
04 Sep 16:29	Share

Imugene Azer-cel Webinar Presentation
04 Sep 10:19	Share

Imugene Webinar - Azer-cel Trial Update
03 Sep 08:26	Share

Three Complete Responses in Azer-Cel Phase 1b Trial
02 Sep 08:44	Share

Imugene ESG Report 2024
30 Aug 18:44	Share

Corporate Governance Statement 2024 and Appendix 4G
30 Aug 18:43	Share

Appendix 4E and Annual Report
30 Aug 18:43	Share

View More

(20min delay)
Last 3.6¢		Change 0.000(0.00%)		Mkt cap ! $267.7M

Open	High	Low	Value	Volume
3.6¢	3.7¢	3.6¢	$101.6K	2.803M

Buyers (Bids)

No.	Vol.	Price($)
47	8424010	3.6¢

Sellers (Offers)

Price($)	Vol.	No.
3.7¢	2276217	6

View Market Depth

No.	Vol.	Price($)
43	8251010	0.036
69	9456441	0.035
26	4987683	0.034
14	1400720	0.033
10	858780	0.032

Price($)	Vol.	No.
0.037	2276216	5
0.038	2398206	8
0.039	4349088	12
0.040	1913152	14
0.041	1221449	11

Last trade - 16.10pm 27/12/2024 (20 minute delay)

IMU (ASX) Chart

IMUGENE LIMITED

Latest Threads

Timeline

Featured News

Latest Videos

Imugene (ASX:IMU) doses first patients in VAXINIA combination study

03 Mar 2023 14:39 (AEDT)

Imugene (ASX:IMU) receives US patent for PD1-Vaxx

10 Feb 2023 10:58 (AEDT)

Imugene (ASX:IMU) advances VAXINIA trial

02 Feb 2023 12:21 (AEDT)

Latest Articles

Imugene kicks off Australian trial for blood cancer treatment

Imugene Ltd has opened its first Australian trial for a Phase 1b clinical trial to test CAR T cell therapy azer-cel

Imugene's azer-cel trial sees tumours temporarily disappear in 3 of 10 patients

Imugene (ASX:IMU) has announced 3 patients in its latest blood cancer treatment trial using azer-cel have responded well with one showing a complete response for over 100 days. A @complete response’ in this case is a complete disappearance of all tumours. The company is focusing o...

Imugene doses first cancer patient in Oasis trial

Imugene Limited (ASX: IMU), has dosed the first patient in the phase 1 clinical trial known as OASIS, which is testing its oncolytic virotherapy drug.The clinical trial is targeting adult patients with advanced or metastatic solid tumours. The primary objective of the trial is to evaluate the saf...

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News